Articles by Louis Garguilo

  1. A Witness To The History of Outsourcing 8/21/2014

    Joe Guiles seems too young and mild-mannered to have been at the outbreak of a revolution that began many years ago. But he witnessed firsthand the inception of what would become the complete penetrability of outsourcing throughout the drug industry. 

  2. Big Pharma Veteran, Peter Bigelow, Will Help “Tell It Like It Is” At Outsourced Pharma West 8/18/2014

    Peter Bigelow is both excited and motivated for Outsourced Pharma West in San Francisco November 10-11, by the targeted subject (drug development and manufacturing outsourcing) and streamlined format (all panelist and attendee discussion; no presentations).

  3. When To Invest In Protein Production: The Risk-Reward Calculation 8/12/2014

    A message to biotech start-ups, scientist-entrepreneurs and life sciences organizations banking on your exciting protein-based drug-discovery programs and technologies: When it comes to the timing of your investment, if you don’t pay now, you might pay (much) more later. 

  4. Learn Pfizer's Guiding Principles For Externalization At Outsourced Pharma West 8/4/2014

    Firelli Alonso-Caplen has been managing outsourcing for 10 years, first at Wyeth and then Pfizer. “The key really is the initial selection process for the CDMO,” she said in a recent conversation regarding our panel at Outsourced Pharma West, in San Francisco, November 10-11. 

  5. ONO Pharmaceutical Strives For Global Sales 7/31/2014

    Gyo Sagara, president, representative director and CEO, challenges his company to enter the cancer field and gain big-pharma relevance.

  6. Give Credit To The U.S. Pharma Industry For Leading Reincorporation 7/15/2014

    You’ve got to give credit to companies in our industry. If punitive U.S. taxation policy is going to drive them to do deals overseas, they are going to go big-time and in style. If they are not allowed to repatriate global dollars in a sensible manner, they will invest them with fanfare abroad.

  7. Pharma Manufacturing In Turkey: No More “Now You See It, Now You Don't” 6/10/2014

    Mention of Turkey in international market discussions can be compared to a game of hide-and-seek: You have to look hard to find it. Unlike the attention-grabbing BRICs (Brazil, Russia, India and China), or the high-flying Asian Tigers (Hong Kong, Singapore, South Korea, and Taiwan), Turkey doesn’t belong to a catchy emerging-market acronym.

    A new report, though, forecasts the pharmaceutical market in Turkey to climb to just under $23 billion in 2015. That should help catch and keep the attention of the pharmaceutical and outsourcing industries.

  8. What If Pfizer Didn't Exist In The U.S.? 5/22/2014

    The most significant intellectual activity available to human beings is asking questions. A study of the creative but unfortunately under-utilized critical skill of questioning is documented in a new book by Warren Berget titled, “A More Beautiful Question: The Power of Inquiry to Spark Breakthrough Ideas,” published by Bloomsbury.

    According to Berget and a variety of CEOs, researchers and other experts in this field, fundamental questioning can benefit start-ups and multi-nationals alike, including assisting in the discovery (or rediscovery) of the core reason for being in business.

    Unfortunately, after what seems like a natural ability and inclination to ask literally thousands of questions when we are children, our schools and workplaces end up discouraging the use of questions. As a result, employees don’t bring the benefits of this skill to our organizations.

  9. PwC Report: Pharmaceutical M&A Increasing; India Growing Sales Market 5/20/2014

    Outsourced Pharma got an early-bird look at the Pharmaceutical and Life Sciences Deals Insights Quarterly analysis of M&A for Q1 2014 announced by press release today by PwC US (PricewaterhouseCoopers LLP).

    The results are impressive for all areas of the Pharmaceutical and Life Sciences (PLS) sector. In total, M&A volume increased 53.1 percent in the first quarter of 2014 compared to the fourth quarter of 2013. Company sentiment is trending in the right direction for more activity.

  10. Marijuana And The Pharmaceutical Industry 5/16/2014

    An intense shot of pain in my back and side dropped me to the floor. It did not subside. We called 911. A single dose of morphine eased the pain enough so the EMTs could put me on a gurney and into the ambulance for the ride to the emergency room. As I lay in the ambulance my mind wandered.

    Morphine is espoused by patients with extreme pain, such as those recovering from major operations like mastectomies. Therefore, anyone over 21 years of age should be able to legally raise poppy plants and/or buy morphine for “recreational” use in their home. We’ll closely monitor any health or other social effects, such as teenage use and car accidents. Sound like a reasonable argument? If not, is there a difference between this thought process and the one of those advocating for legalizing marijuana in the U.S.?